[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:t-11-14":3},{"name":4,"total":5,"recruiting":6,"trials":7},"t(11;14)",11,9,[8,16,23,29,36,43,49,55,61,67,74],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06115135","A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed\u002FRefractory Multiple Myeloma",[12],"Phase 2","RECRUITING","2026-08-26T02:15:11.740957Z","2026-05-05T02:43:29.700243Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04973605","A Phase 1b\u002F2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma",[20],"Phase 1\u002FPhase 2","2026-08-26T02:19:28.327680Z","2026-05-05T02:43:29.683738Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05530421","Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed\u002FRefractory Multiple Myeloma",[12],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:29.229063Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06042725","MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma",[33],"Phase 1","2026-08-03T03:51:46.071131Z","2026-05-05T02:43:28.546724Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT06084936","A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed\u002FRefractory Mantle Cell Lymphoma",[40],"Phase 3","2026-08-26T02:18:51.009190Z","2026-05-05T02:43:28.290108Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06953960","A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and\u002For Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)",[20],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.206601Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT05910801","Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",[12],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:27.931684Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[12],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.813302Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[12],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":68,"title":69,"phases":70,"status":71,"updated_at":72,"content_modified":73},"NCT04847453","Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis",[33],"ACTIVE_NOT_RECRUITING","2026-08-03T02:38:34.966507Z","2026-05-05T02:43:29.693654Z",{"nct_id":75,"title":76,"phases":77,"status":71,"updated_at":78,"content_modified":79},"NCT05451771","Venetoclax-Dexamethasone in Relapsed and\u002For Refractory t(11;14) Amyloidosis",[20],"2026-08-03T03:31:44.965184Z","2026-05-05T02:43:27.816636Z"]